Feasibility of SBIRT-PN

计划入组 86 人 · 首次发布于 2017 年 2 月 17 日

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

计划入组 120 人 · 首次发布于 2002 年 5 月 31 日

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

计划入组 240 人 · 首次发布于 2002 年 6 月 17 日

PN-032/PN-056

(PN-152,243)/PN-196,444

PN-10943

Commodore Metals Corp

Protagonist Therapeutics

United States

MedImmune Ltd.

United Kingdom

MediciNova Secures $30 Million Standby Equity Agreement to Advance Neurological and Fibrotic Disease Programs

Mirdametinib Demonstrates Significant Tumor Reduction and Improved Quality of Life in NF1-Associated Plexiform Neurofibroma

Mirdametinib Shows Deep Responses in NF1-Associated Plexiform Neurofibromas